Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 01, 2021 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

NANTES, France, Sept. 01, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173) today announced it will present at the H.C. Wainwright 23rd Annual Global Investment Conference. The...
August 26, 2021 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics and ARCAGY-GINECO Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Pembrolizumab in Ovarian Cancer

Clinical trial sponsored and conducted by the French oncology cooperative group ARCAGY-GINECO and supported by Merck Sharp & Dohme Corp. (MSD), a subsidiary of Merck & Co., Inc., Kenilworth,...
August 25, 2021 12:00 ET | Source: OSE Immunotherapeutics

Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome

PARIS and NANTES, France, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group, and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE), a French biotech,...
August 24, 2021 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Upcoming Investor Conferences and R&D Day

NANTES, France, Aug. 24, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) today announced that the Company will be present at the following investor events: H.C....
July 19, 2021 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Voluntary Pause of Enrollment in the CoVepiT Phase 1 Study

NANTES, France, July 19, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today announced a voluntary and temporary pause of enrollment and dosing in its ongoing...
July 09, 2021 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Receives a €10 Million Payment Corresponding to the First Tranche of the Financing Granted by the European Investment Bank

This financing will further support the progress and expansion of OSE Immunotherapeutics’ lead clinical development programs in therapeutic areas with high unmet medical needs.This €10 million payment...
June 30, 2021 01:30 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Manufacturing Agreement with Cenexi for Clinical Batches of CoVepiT, OSE’s Multi-Target Second-Generation COVID-19 Vaccine

NANTES, France and FONTENAY-SOUS-BOIS, France, June 30, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) and Cenexi, a French contract development and manufacturing...
June 24, 2021 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Reports on its 2021 Virtual Combined General Shareholder’s Meeting

NANTES, France, June 24, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) today announced that all the resolutions submitted to a vote at the Combined General...
May 27, 2021 12:00 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics and the FoRT Foundation Announce Initiation of a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (nivolumab) in Non-Small Cell Lung Cancer

This clinical trial will be sponsored and conducted by the Italian Oncology Foundation FoRT and supported by Bristol Myers Squibb and OSE Immunotherapeutics. The study will explore the strategy of...
May 26, 2021 01:30 ET | Source: OSE Immunotherapeutics

OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine

First-in-human study evaluating CoVepiT, a multi-variant T cell COVID-19 vaccine for people at risk and vulnerable populations.CoVepiT is a peptide-based vaccine aiming to induce CD8+T-cell-mediated...